Title:
OPTIMIZED CHIMERIC ANTIGEN RECEPTOR TARGETING IL13Rα2 AND USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2024/066026
Kind Code:
A1
Abstract:
Provided is a chimeric antigen receptor targeting IL13Rα2, comprising: (1) an optimized anti-IL13Rα2 scFv sequence; (2) an optimized hinge region/spacer region; (3) a transmembrane region (TM); (4) a CD28 costimulatory domain and a 4-1BB costimulatory domain; and (5) a CD3ζ signaling domain. Also provided are a nucleic acid molecule encoding the chimeric antigen receptor, a vector comprising the nucleic acid molecule, an immune effector cell (e.g., a T cell or an NK cell) engineered to express the chimeric antigen receptor, and a use of the engineered immune effector cell in treating diseases related to the expression of IL13Rα2, for example, glioma.
Inventors:
ZHONG XIAO SONG (CN)
BAI YUE (CN)
BAI YUE (CN)
Application Number:
PCT/CN2022/136205
Publication Date:
April 04, 2024
Filing Date:
December 02, 2022
Export Citation:
Assignee:
CARRIAGE PHARMACEUTIC BEIJING CO LTD (CN)
International Classes:
C07K19/00; A61K39/00; A61P35/00; C12N5/10; C12N15/62; C12N15/867
Domestic Patent References:
| WO2021154543A2 | 2021-08-05 |
Foreign References:
| CN107002084A | 2017-08-01 | |||
| CN112236151A | 2021-01-15 | |||
| CN114014941A | 2022-02-08 | |||
| CN104936621A | 2015-09-23 |
Attorney, Agent or Firm:
ZHONGZI LAW OFFICE (CN)
Download PDF: